BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed price. Currency in USD

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212-546-4000
http://www.bms.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full-time employees23,300

Key executives

NameTitlePayExercisedYear born
Dr. Giovanni CaforioChairman & CEO6.37MN/A1965
Mr. Charles A. BancroftExec. VP of Global Bus. Operations & CFO3.58M1.67M1960
Dr. Thomas J. Lynch Jr.Exec. VP & Chief Scientific Officer2.96MN/A1961
Ms. Sandra Leung Esq.Exec. VP & Gen. Counsel2.95MN/A1961
Mr. Louis S. SchmuklerSr. VP and Pres of Global Product Devel. & Supply2.08MN/A1956
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Corporate governance

Bristol-Myers Squibb Company’s ISS governance QualityScore as of 1 April 2019 is 3. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes